Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard Louis

Showing results (131-140 of 290) with videos related to

Pageof 29
Sort By:
Patient Preference and Adherence|July 18, 2018
Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover studySéverine Vermeire, François D'heygere, Antoine Nakad, et al.
Inflammatory Bowel Diseases|September 4, 2024
Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's DiseaseJulian Panés, Edouard Louis, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|August 29, 2024
The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel DiseaseDavid Laharie, Lucine Vuitton, Arnaud Bourreille, et al.
Gut|August 25, 2022
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activityNicolas Pierre, Vân Anh Huynh-Thu, Thomas Marichal, et al.
Pharmacogenetics and Genomics|September 27, 2006
The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's diseaseVinciane Dideberg, Emilie Théâtre, Frédéric Farnir, et al.
Advances in Therapy|August 6, 2024
Content Validity and Psychometric Evaluation of the Crohn's Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn's DiseaseEdouard Louis, Wan-Ju Lee, Leighann Litcher-Kelly, et al.
The American Journal of Gastroenterology|May 5, 2026
Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE StudyEdward V Loftus, Namita Joshi, Bruce E Sands, et al.
Thorax|August 8, 2020
Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3pJulien Guiot, Maureen Cambier, Amandine Boeckx, et al.
Respiratory Research|April 15, 2023
Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosisJulien Guiot, Monique Henket, Claire Remacle, et al.
Scandinavian Journal of Gastroenterology|February 27, 2024
Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn's diseaseSophie Vieujean, Romain Gillard, Pierre Delanaye, et al.
Pageof 29

Showing results (131-140 of 290) with videos related to

Sort By:
Pageof 29
Patient Preference and Adherence|July 18, 2018
Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover studySéverine Vermeire, François D'heygere, Antoine Nakad, et al.
Inflammatory Bowel Diseases|September 4, 2024
Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's DiseaseJulian Panés, Edouard Louis, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|August 29, 2024
The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel DiseaseDavid Laharie, Lucine Vuitton, Arnaud Bourreille, et al.
Gut|August 25, 2022
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activityNicolas Pierre, Vân Anh Huynh-Thu, Thomas Marichal, et al.
Pharmacogenetics and Genomics|September 27, 2006
The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's diseaseVinciane Dideberg, Emilie Théâtre, Frédéric Farnir, et al.
Advances in Therapy|August 6, 2024
Content Validity and Psychometric Evaluation of the Crohn's Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn's DiseaseEdouard Louis, Wan-Ju Lee, Leighann Litcher-Kelly, et al.
The American Journal of Gastroenterology|May 5, 2026
Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE StudyEdward V Loftus, Namita Joshi, Bruce E Sands, et al.
Thorax|August 8, 2020
Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3pJulien Guiot, Maureen Cambier, Amandine Boeckx, et al.
Respiratory Research|April 15, 2023
Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosisJulien Guiot, Monique Henket, Claire Remacle, et al.
Scandinavian Journal of Gastroenterology|February 27, 2024
Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn's diseaseSophie Vieujean, Romain Gillard, Pierre Delanaye, et al.
Pageof 29